A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Stargardt disease
- Focus Therapeutic Use
- Sponsors IVERIC bio
- 26 Feb 2019 According to an OphthoTech Corporation media release, top-line data expected to be available in the second half of 2020.
- 01 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2018 According to an OphthoTech Corporation media release, initial top-line data expected to be available in 2020.